Latest Articles
Janel Parrish opens up about endometriosis surgery - The Express Tribune
Janel Parrish opens up about endometriosis surgery The Express Tribune
Published: June 26, 2024, 7 a.m.
Chronic endometritis multiplies the recurrence risk of endometrial polyps after transcervical resection of endometrial polyps: a prospective study - BioMed Central
Chronic endometritis multiplies the recurrence risk of endometrial polyps after transcervical resection of endometrial polyps: a prospective study BioMed Central
Published: June 26, 2024, 7 a.m.
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
Frequently Searched Questions: Uterine Cancer - Roswell Park Comprehensive Cancer Center
Frequently Searched Questions: Uterine Cancer Roswell Park Comprehensive Cancer Center
Published: June 24, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective - BioMed Central
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective BioMed Central
Published: June 22, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
The Supreme Court Overruled Roe Two Years Ago, Ending Right To Abortion. Birth Control May Be Next - Forbes
The Supreme Court Overruled Roe Two Years Ago, Ending Right To Abortion. Birth Control May Be Next Forbes
Published: June 21, 2024, 7 a.m.
Link copied to clipboard!